Table 5.
Multivariate Cox analysis of the association between expression levels of pentose phosphate pathway-related proteins in metastatic breast cancers and overall survival.
| Included parameters | Bone metastasis | Lung metastasis | ||||
|---|---|---|---|---|---|---|
| Overall survival | Overall survival | |||||
| HR | 95% CI | p value | HR | 95% CI | p value | |
| ER status | ||||||
| Negative versus positive | 1.768 | 0.113–27.61 | 0.685 | n/a | n/a | n/a |
| PR status | ||||||
| Negative versus positive | 0.453 | 0.119–1.730 | 0.247 | n/a | n/a | n/a |
| HER-2 status | ||||||
| Negative versus positive | 1.025 | 0.217–4.833 | 0.975 | n/a | n/a | n/a |
| Ki-67 LI | ||||||
| ≤14 versus >14 | 0.961 | 0.031–29.98 | 0.982 | 11.853 | 1.841–76.30 | 0.009 |
| Molecular subtype | ||||||
| TNBC versus non-TNBC | 0.647 | 0.002–254.8 | 0.886 | n/a | n/a | n/a |
| 6PGL | ||||||
| Negative versus positive | 4.180 | 1.160–15.06 | 0.029 | n/a | n/a | n/a |
| 6PGDH | ||||||
| Negative versus positive | n/a | n/a | n/a | 1.362 | 0.130–14.29 | 0.797 |
HR, hazard ratio; CI, confidential interval; ER, estrogen receptor; n/a, not applicable; PR, progesterone receptor; HER-2, human epidermal growth factor-2; LI, labeling index; TNBC, triple negative breast cancer; 6PGL, 6-phosphogluconolactonase; n/a, not applicable; 6PGDH, 6-phosphogluconate dehydrogenase.